SAN DIEGO, Calif. — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced positive topline results from its pivotal Phase 3 HOPE-3 trial evaluating Deramiocel, the Company’s investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD). “HOPE-3...
Latest News
SAN DIEGO, Calif. — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company has been granted an in-person Type-B meeting with the U.S. Food & Drug Administration (FDA) scheduled for late March. In the...
San Diego — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced that the Company presented the 18-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002,...
SAN DIEGO, Calif. — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of...
SAN DIEGO, Calif. — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced a regulatory update for its Biologics License Application (BLA) for Deramiocel, the Company’s investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD). This update follows a recent...
THOUSAND OAKS, Calif. — Capsida Biotherapeutics today announced new preclinical data supporting the potential of Capsida’s gene therapy candidate, CAP-002, to achieve levels of gene supplementation necessary to correct neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations. Gene therapy for genetic epilepsy due to STXBP1...
Capsida previously received FDA Orphan Drug Designation and IND clearance to initiate the SYNRGY Phase 1/2a clinical trial for CAP-002 THOUSAND OAKS, Calif. — Capsida Biotherapeutics (“Capsida”) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its CAP-002 program. CAP-002 is the company’s investigational...
San Francisco, California – Grant of up to $11 million will fund a clinical trial at UCSF that uses a smarter new CAR-T guided by precision technology. A type of gene therapy called CAR-T that has extended survival for thousands of patients with leukemia and other blood cancers is being...
Basel, Switzerland – Chimeric antigen receptor (CAR) T-cell therapy represents one of the most significant advancements in modern immunotherapy. Originally developed to treat hematologic malignancies, this approach involves genetically modifying a patient’s T cells to express an artificial receptor capable of recognizing specific tumor antigens. Upon re-infusion, these tailored T...
HOUSTON, Texas – Researchers at Texas Children’s Cancer Center and the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist published results of a phase I clinical trial of a novel immunotherapy for high-risk sarcomas in the journal Nature Cancer. The therapy...